XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
H
H

Hikma


Berita

Hikma Completes Xellia Acquisition

BRIEF-Hikma Completes Xellia Acquisition Sept 10 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HIKMA PHARMACEUTICAL - HIKMA COMPLETES XELLIA ACQUISITION Source text for Eikon: ID:nRSJ5017Da Further company coverage: HIK.L
H

US allows increased production of Takeda's ADHD drug and its generics to address shortage

CORRECTED-US allows increased production of Takeda's ADHD drug and its generics to address shortage Corrects headline and paragraph 1 to make clear Takeda's drug is not in shortage Sept 4 (Reuters) - The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's 4502.T ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the copies in the United States.
H
T

Draegerwerk, Hikma, Novartis

EUROPE RESEARCH ROUNDUP-Draegerwerk, Hikma, Novartis Sept 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Draegerwerk, Hikma and Novartis, on Tuesday. HIGHLIGHTS * Draegerwerk DRWG.DE : Jefferies raises to hold from underperform * Hikma HIK.L : Berenberg raises to buy from hold * Munters Group AB MTRS.ST : Jefferies raises to buy from hold * Novartis AG NOVN.S : Jefferies cuts to hold from buy * Swedencare AB (Publ) SECARE.ST : J
A
A
A
B
B
B
C
D
G
H
H
N
S
T
U
A
P

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug By Mike Scarcella Aug 27 (Reuters) - Drug companies Jazz JAZZ.O and Hikma HIK.L must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices, a U.S. judge in California has ruled. U.S. District Judge Richard Seeborg’s ruling on Monday night in San Francisco cleared a path to trial on some claims in the long-running multidistrict legal act
H

Danske Bank, Lotus Bakeries NV, Vesuvius

EUROPE RESEARCH ROUNDUP-Danske Bank, Lotus Bakeries NV, Vesuvius Aug 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Lotus Bakeries NV and Vesuvius, on Tuesday. HIGHLIGHTS * Abrdn Plc ABDN.L : Morgan Stanley raises target price to 160p from 149p * Danske Bank DANSKE.CO : Morgan Stanley initiates coverage with overweight rating * Lotus Bakeries NV LOTB.BR : Berenberg raises target price to EUR 10,300 from EUR 9,000 *
A
A
A
B
C
D
E
F
H
H
K
L
M
M
N
O
S
S
S
S
S
H
A
S
U

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up
A
A
A
A
B
B
B
C
C
D
D
E
G
G
H
H
H
I
K
O
B

London's FTSE 100 ends lower as top companies trade ex-dividend

UPDATE 1-London's FTSE 100 ends lower as top companies trade ex-dividend For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100, FTSE 250 down 0.3% Heavyweights trade without dividend entitlement Beazley upgrades 2024 combined ratio forecast, shares surge Updated at 1425 GMT By Purvi Agarwal and Shubham Batra Aug 8 (Reuters) - London's FTSE 100 slipped on Thursday, tracking global market sentiment, while investors assessed corporate up
A
B
H
S
U

STOXX 600 recovers early losses on US jobs data relief

UPDATE 2-STOXX 600 recovers early losses on US jobs data relief For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo rebounds on positive read-across from Lilly Siemens jumps after profit beat Allianz rises on Q2 beat Deutsche Telekom up after increase in Q2 core earnings STOXX 600 up 0.1% Updates at 1600 GMT By Ankika Biswas and Pranav Kashyap Aug 8 (Reuters) - Europe's benchmark stock index recouped early losses to close slightly highe
B
D
H
P
S
S
S
A
Z
E
F
U
G

That unwind feeling

LIVE MARKETS-That unwind feeling STOXX 600 down 1.1% Volatility above 23 Banks, tech down Some UK earnings please Nasdaq futures fall Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com THAT UNWIND FEELING European shares got off to a lower start on Thursday, bringing about the feeling that the yen carry trade unwind is not over yet.
B
D
H
P
E
F
U
G

UK's Hikma gains on upbeat annual outlook, sturdy H1 performance

BUZZ-UK's Hikma gains on upbeat annual outlook, sturdy H1 performance ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 5.3% at 1,937p ** Stock among top gainers in the FTSE 100 index .FTSE ** Co forecasts its annual revenue to grow in the range of 6% to 8%, up from previous outlook of 4% to 6% ** Sees FY core operating profit of $700 m
H
U

Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln

BRIEF-Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln Aug 8 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HY INTERIM DIVIDEND OF 32 CENTS PER SHARE, UP 28% UPGRADES GROUP GUIDANCE SEES FY GROUP REVENUE GROWTH OF 6% TO 8%, UP FROM 4% TO 6% SEES FY GROUP CORE OPERATING PROFIT OF $700 MILLION TO $730 MILLION, UP FROM $660 MILLION TO $700
H

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U

NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US

BUZZ-NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US ** Shares of AFT Pharmaceuticals AFT.NZ rise as much as 1.6% to NZ$3.15, their highest level since June 18 ** Pharmaceutical co signs agreement with Hikma Pharmaceuticals USA to distribute its patented COMBOGESIC tablets, used for adult pain management, to selec
H

UK corporate earnings week ahead

DIARY-UK corporate earnings week ahead Aug 2 (Reuters) - Diary of U.K (.FTSE) corporate earnings for the week ahead UK EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 06-Aug-2024 06:00 IHG.L InterContinental Hotels Group PLC Half Year 2024 InterContinental Hotels Group PLC Earnings Release 07-Aug-2024 06:00 GLEN.L Glencore PLC Half Year 2024 Glencore PLC Earnings Release 07-Aug-2024 06:00 CCH.L Coca Cola HBC AG Half Year 2024 Coca Cola HBC AG Earnings Release 08-Aug-2024 NTS HIK
B
G
H
H
P
U

Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says

BRIEF-Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says July 22 (Reuters) - Food and Drug Administration: FDA: HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF ACETAMINOPHEN INJECTION, 1000MG/100ML, (10MG/ML) BAGS FDA-HIKMA RECALL DUE TO INDIVIDUAL UNIT OF AC
H

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .
H
T

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.
H
T

Hikma Acquires Xellia’S Assets

BRIEF-Hikma Acquires Xellia’S Assets June 17 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HIKMA PHARMACEUTICAL - HIKMA ACQUIRES XELLIA’S ASSETS HIKMA: HIKMA WILL PAY A CASH CONSIDERATION OF $135 MILLION, AND AN ADDITIONAL CONTINGENT CONSIDERATION OF UP TO $50 MILLION HIKMA: ACQUISITION WILL ADD EIGHT APPROVED AND MARKETED INJECTABLE PRODUCTS T
H



Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.